Current Treatment Landscape in HER2+ Breast Cancer

Insights from ESMO Breast 2024 Annual Meeting
C

ESMO Breast 2024 Insights: "FeDeriCa Trial Final Analysis - Fixed-Dose Combination of Pertuzumab & Trastuzumab for Subcutaneous Injection + Chemo in HER2+ eBC"

By Insights from ESMO Breast 2024 Annual Meeting FEATURING Christian Jackisch
By Insights from ESMO Breast 2024 Annual Meeting FEATURING Christian Jackisch
263 views
June 21, 2024
Comments 0
Login to view comments. Click here to Login
08:04

New Insights Into Optimizing HER2-Directed Therapy in the Curative S…

Adrienne Waks

187 views
09:59

Neoadjuvant & Adjuvant Therapy for HER2+, High-Risk, Early Stage BC

UChicago Medicine

R. Nanda

284 views
17:16

The Management of HER2+ eBC: Case Discussion and Recent Updates

Northwell Health

F. Esteva

275 views
09:24

ASCO® 2024 Summary: "Treatment and Outcomes in Select Subpopulations…

2024 ASCO® Annual Meeting Insights Hub

L. Carey

349 views
25:08

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

4.2K views
20:09

Optimizing Treatment in Early Stage HER2+ BC

2023 Best of Breast Conference

R. L. Mahtani

541 views
10:54

De-Escalation of Adjuvant Therapy in Early Stage HER2+ Breast Cancers

Yale Cancer Center

L. Pusztai

1.1K views
06:40

Pertuzumab & Trastuzumab in HER2+ BC: IV vs. SQ Administration, NCCN…

Parvin Peddi

750 views
03:31

Current Adjuvant Treatment in HER2+ BC

Total Health

G. Vidal

250 views
10:48

52 y/o With HER2+ De Novo mBC: Case Presentation and Panel Discussion

Total Health

P. Sharma, M. Telli, K. Kalinsky

260 views